. . . this sets up an interesting situation . . . will Jacobus even be permitted to give away their product if CPRX gains approval? . . . look at colchicine -- a drug that was a grandfathered generic for decades was sold to gout sufferers for 10 cents a pill until a few years ago -- that's when a big pharma took it through FDA trials and approval . . . suddenly, BP's version was by law the only one available in the U.S. and it was initially, I think, north of $5 per pill . . . that said, with CPRX having the accelerated review process -- granted by its "breakthrough" status -- I'd be very surprised to see Jacobus win out . . . we'll see . . .
. . . that's a pretty safe bet, r7 . . . I'm really just hoping CLDN's results are good enough to further validate the genetic engineering space, because I've got a lot of bets spread over that technology . . . good luck . . .
. . . "There is no way good news is coming with a drop like this" . . . well, m3, since you obviously don't know a thing about biotech betting, permit me to clue you in . . . if there "really was no way" as you claim, the stock would be well under $5 at his point . . . day traders and momentum players are clearly exiting the field . . . those of us who have done the DD and can afford the risk will simply wait for the data . . . adios and good luck . . .
. . . the overall market can always move stocks lower, j3 . . . but if the results are strongly positive, I think CLDN is a $100+ stock in short order . . . in that case, why quibble over a few bucks at these levels . . . big pharma has already hedged their bets on genetic engineering with tie-ups to Cellectis, Uniqure, Bluebird, Sangamo and a host of others . . . however, the upside here exists only because we don't the outcome, so only wager what you can comfortably afford to lose . . .
. . . since I don't know your rationale for adding more here, d5, I would say that -- just for myself, I might add additional shares if CLDN falls below my average price ($11.52) . . . that said, I try not to add beyond my targeted dollar amount, particularly on a binary event -- even when the drug has "breakthrough" status . . . if you have what you thought was a near full complement of CLDN shares already, you could diversify and still play in the same space by buying QURE, for instance, which just partnered its genetic cardio therapy with BMY . . . good luck in any case . . .
. . . then again . . . maybe it's just blind pumper madness . . . grasping for any straw that might make this pig look like a winner . . . and, yet, my stinkin' arna shares remain under water . . .
. . . interesting post, mc . . . I would also speculate that BMY may have teamed with QURE, figuring that it would have an edge in Europe . . . having already won approval there for Glybera, QURE knows the regulatory ropes . . . moreover, I think Europe – fully realizing the billions that are at stake here -- has shown signs that it would like to capture the global leadership position in genetic-engineered therapies . . . we’ll see . . .
. . . that's how it appears anyway based the utter nonsense posted here ad nauseam by some areniacs . . . then again maybe it’s just their natural response to OREX’s market share gains . . . Contrave’s got ‘em shakin’ in their boots . . . go figure . . .
maybe you don't get it, bw, because you don't understand market cap . . . srpt's is a bloated $561 million . . . that, in my estimation, reflects an abundance of speculation . . . just sayin' . . .
. . . and, yet, BMRN on 2/25 issued this statement: "Drisapersen has Orphan, Fast Track and Breakthrough Therapy designation and is currently under rolling review as part of a New Drug Application (NDA) with the Food and Drug Administration. Drisapersen, a potential first-to-market and best-in-class product for treating a large population of patients with a rare, fatal genetic disease represents up to 10,000 DMD patients. Follow-on products leverage the same technology platform and target an additional 35,000 DMD patients in BioMarin's commercial territories. All of the pipeline products added to BioMarin's portfolio through the acquisition leverage a proprietary RNA-modulating technology platform for the treatment of various genotypes of DMD and other genetic disorders. BioMarin expects to complete the NDA submission for drisapersen in April 2015." . . . you'll likely find out more in just a few weeks . . .